Corporate Culture
- Vision
- Innovation leader in nutrition science and technology, first choice of customers
- Mission
- Advance nutrition science and technology, deliver value to health
- Core Values
- Service, Innovative, Responsible, Initiative, Open
SIRIO is firmly rooted in technology, with R&D investment totaling RMB110 million in 2023. Backed by over 30 years of expertise, SIRIO has built a leading multidisciplinary R&D team, established five global R&D centers, obtained 80+ domestic and international invention patents, and developed a portfolio of more than 6000 established nutraceutical formulations. We work alongside you to transform scientific leadership into product excellence and a lasting competitive edge.
1993
SIRIO was founded
Began pharmaceutical manufacturing
1999
Began manufacturing nutraceutical products
2002
Launched export operations
2003
Achieved GMP certification for pharmaceuticals
Expanded to North American and European markets
2007
Opened a second facility at the Shantou production site, expanding to multi-dosage manufacturing
2010
Opened US Branch
2013
Launched the plant-based softgel production line
2015
Established Ma'anshan Health Industrial Park
2016
Acquired Ayanda GmbH (Germany), now is Sirio Pharma Germany
Obtained UL certification (USA)
2019
Listed on the A-share market (300791.SZ)
2021
Launched the digital transformation initiative for the health and wellness industry
2022
Established the Shanghai R&D Center
Launched the Ma’anshan smart warehouse
2023
Acquired Best Formulations LLC (USA)
Started operations at Zhuhai Bonded Factory
2024
Launched a new automated packaging line in Sirio Pharma Germany
NF-Ubidecarenone Chewable Gels included in the United States Pharmacopeia
Launched the E-Cube Bioinspired Efficacy Technology Platform
仙乐健康业务覆盖50多个国家与地区，累计服务全球70亿人次